agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2.
http://www.ncbi.nlm.nih.gov/pubmed/11801628
me auto copio y pego según mi opinion que acabo de escribir en ganarpelo.org:
El tema de la indometacina despierta interés porque presenta mayor afinidad por la COX 1, y la cox1 se acopla mejor a la prostaglandina D2 sintasa lipocalina que a priori pareciera ser la que está involucrada en nuestro problema:
http://med.javeriana.edu.co/publi/vnive ... alinas.pdf
Por otro lado:
Indomethacin-induced Reduction in CRTH2 in Eosinophilic Pustular Folliculitis (Ofuji’s Disease): A Proposed Mechanism of Action
Takahiro Satoh, Chieko Shimura, Chiyako Miyagishi and Hiroo Yokozeki
Department of Dermatology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
Eosinophilic pustular folliculitis is an inflammatory skin disease characterized by pruritic follicular papulopustules. It is usually resistant to topical and/or systemic corticosteroids, but it responds well to systemic indomethacin. We report here two patients with classical-type disease who were treated with systemic indomethacin. As indomethacin is an inhibitor of cyclo-oxygenases and a potent agonist of the prostaglandin D2 (PGD2) receptor, CRTH2 (chemoattractant receptor homologous molecule expressed on Th2 cells), we investigated the effects of indomethacin on CRTH2 expression by leukocytes. CRTH2 was expressed on blood eosinophils and lymphocytes. In vitro treatment with indomethacin suppressed the expression of CRTH2 on these cells. In addition, systemic treatment with indomethacin reduced eosinophil CRTH2 expression in another patient in association with improvement of skin lesions and blood eosinophilia. A number of inflammatory cells expressed haematopoietic PGD synthase, an essential enzyme for generating PGD2 in skin lesions of eosinophilic pustular folliculitis. A PGD2-CRTH2 interaction may be involved in the pathogenesis. Moreover, indomethacin may exert its therapeutic effect via reducing CRTH2 expression, as well as by inhibiting PGD2 synthesis. Key words: CRTH2; eosinophils; indomethacin; prostaglandin D2; PGD synthase.
Acá me encuentro un poco confundido porque hay algun que otro paper:
J Immunol. 2002 Feb 1;168(3):981-5.
Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2.
Hirai H, Tanaka K, Takano S, Ichimasa M, Nakamura M, Nagata K.
Source
R&D Center, BML, 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan.
Abstract
Indomethacin is a widely used nonsteroidal anti-inflammatory drug and is generally known to exhibit its multiple biological functions by inhibiting cyclooxygenases or activating peroxisome proliferator-activated receptors. In this study, we present evidence demonstrating that the novel PGD(2) receptor chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) is another functional target for indomethacin. Indomethacin induced Ca(2+) mobilization in CRTH2-transfected K562 cells at submicromolar concentrations (approximate EC(50), 50 nM) in a G(alphai)-dependent manner as PGD(2) did. Other nonsteroidal anti-inflammatory drugs (aspirin, sulindac, diclofenac, and acemetacin) had no such effect even at micromolar concentrations. In chemotaxis assay, three CRTH2-expressing cell types, Th2 cells, eosinophils, and basophils, were all significantly attracted by indomethacin (EC(50), 50-500 nM) as well as by PGD(2) (EC(50), 2-20 nM), and the effects of indomethacin were blocked by anti-CRTH2 mAb. These results suggest the involvement of CRTH2 in mediating some of therapeutic and/or unwanted side effects of indomethacin, independently of cyclooxygenases and peroxisome proliferator-activated receptors.
que declara a la indometacina agonista del receptor CRTH2( en teoria nuestro enemigo). Sin embargo, en este paper que puse del 2009, pareciera que disminuye la sintesis del receptor CRTH2, y a la vez de la PGD2 sintasa....
Podria ser que la indometacina es agonista del CRTH2, pero su potencia como inhibidor dual de ambas COX, reductor de la PGD2 sintasa hematopoyética directa y de la lipocalina indirecta ( via cox1), además de disminuir la exprsion del receptor crth2, sea muuuuuy superior a su efecto agonista sobre el CRTH2 y genere un efecto tricogeno.
Y si a eso le ponemos minoxidil que es un "simil" prostaglandina crecepelo... la cosa se vuelve interesante.
saludos